TGFB1 and recessive dystrophic epidermolysis bullosa: Although levels of active TGF-β1 can be seen in different diseases, and may reflect processes such as wound-healing, active inflammation and autoimmune events, we propose here that active TGF-β1 might serve as a biomarker in the follow up of patients with RDEB; a possibility that would have to be evaluated in more detailed clinical trials under strict regulatory rules.